Transition Therapeutics Inc (TTHI)

1.52
0.00 0.32
Prev Close 1.52
Open 1.54
Day Low/High 1.52 / 1.57
52 Wk Low/High 0.66 / 2.75
Volume 12.42K
Avg Volume 88.90K
Exchange
Shares Outstanding 38.88M
Market Cap 59.10M
EPS -1.10
Div & Yield N.A. (N.A)
Alkermes, Arena: Volume Movers

Alkermes, Arena: Volume Movers

Alkermes, Arena and other stocks were poised to move on above-average volume Friday.

10 Alzheimer's Disease Treatment Stocks

10 Alzheimer's Disease Treatment Stocks

Despite recent setbacks, investors are still searching for a company to unlock a treatment for Alzheimer's disease.

Elan And Transition Therapeutics Announce Topline Summary Results Of Phase 2 Study And Plans For Phase 3 For ELND005 (Scyllo-inositol )

Elan Corporation, plc (NYSE: ELN) and Transition Therapeutics, Inc (TSX: TTH, NASDAQ:TTHI) today announced the results of a Phase 2 placebo-controlled study in 351 patients with mild to moderate Alzheimer’s...

Transition Therapeutics to Pay Eli Lilly $1M

Transition Therapeutics to Pay Eli Lilly $1M

Biopharmaceutical company Transition Therapeutics is set to pay Eli Lilly $1 million to acquire exclusive rights to develop preclinical compounds for diabetes.

CardioNet, Cyclacel: Midday Volume Plays

CardioNet, Cyclacel: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Tuesday's session.

Safety Dogs Elan Alzheimer's Drug; Seattle Genetics Finds New Partner: BioBuzz

Safety Dogs Elan Alzheimer's Drug; Seattle Genetics Finds New Partner: BioBuzz

Elan is forced to cut high doses of its Alzheimer's drug ELND005 from a mid-stage study, while Seattle Genetics hooks up with a Japanese drug maker.

Health Winners & Losers: Biogen

Health Winners & Losers: Biogen

Biogen sinks on Tysabri-related news.